A Phase III Randomized, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma - Related Studies

A Phase III Randomized, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

This study is ongoing, but not recruiting participants.

Study NCT00105443. Last updated on September 27, 2006. Information provided by Bayer

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer
		Liver Cancer
		Hepatocellular Carcinoma (HCC)

2	Additional conditions recognized in this trial
		Carcinoma
		Carcinoma, Hepatocellular
		Liver Neoplasms

3	More general conditions related to this trial
		Adenocarcinoma
		Digestive System Diseases
		Digestive System Neoplasms
		Liver Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial

4	Interventions listed in this trial
		Nexavar (Sorafenib, BAY43-9006)

5	Additional drug interventions recognized in this trial
		Sorafenib

6	More general drug interventions related to this trial
		Antineoplastic Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protein Kinase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Bayer